anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Children often present to pediatricians and pediatric endocrinologists because of abnormal body growth, including both childhood growth failure and, less commonly, overgrowth. Sometimes the cause is evident, for example, growth hormone deficiency for growth failure and growth hormone excess for overgrowth. In other children, the etiology remains unknown despite extensive evaluation, resulting in the unhelpful diagnosis of severe idiopathic short stature or tall stature. These conditions are quite heterogeneous, including children with isolated growth disorders and others who also have other abnormalities such as developmental delay or a constellation of congenital anomalies (syndromic growth disorders). Some cases of severe growth disorders have a polygenic inheritance while others appear to be inherited as a monogenic trait - recessive, dominant or X-linked. Because of recent advances in DNA sequencing technology, it is now feasible to sequence the exome (portion of the genome that encodes gene exons) in families with monogenic disorders and thereby determine the underlying molecular etiology.

We therefore propose a study to identify novel genetic causes of idiopathic growth disorders using whole-exome sequencing. The primary goal of this study is to identify novel causes of childhood growth disorders in order to improve clinical diagnosis, to provide a more precise characterization of associated medical problems, prognosis, and response to treatment based on etiology, and to gain new insights into the regulation of human growth, which may eventually lead to new therapeutic approaches.

Subjects will include children and adults with a clearly recognizable phenotype that includes either short stature or tall stature and a pedigree that strongly suggests a monogenic inheritance. Both syndromic and non-syndromic growth disorders and both proportionate and disproportionate growth disorders will be included. Affected and unaffected family members (who have informative meiotic inheritance relationships to the proband or index case) will also be studied because of their importance for this genetic approach. The phenotype will be characterized by medical history, physical exam, body measurements, and laboratory evaluation. Blood and saliva samples will be collected for whole-exome sequencing and single nucleotide polymorphism (SNP) array analysis. Candidate sequence variants will typically be verified by Sanger sequencing.
Pregnancy and delivery can function as a "stress test" for future development of cardiovascular disease and metabolic disorders, with gestational diabetes and excessive weight gain during pregnancy leading to worse outcomes later in a mother's life. The prevalence of both conditions continues to increase with the obesity epidemic, highlighting the urgent need for successful interventions to reverse maternal weight gain and promote normal blood sugars. The early postpartum period provides a critical opportunity to address diet behaviors that are related to both weight and diabetes. Postpartum medically-tailored meal delivery is a novel approach that may allow for improved blood sugar control and weight loss in a traditionally hard-to-engage patient population. There is currently no available data on the cost, feasibility, or effectiveness of providing medically-tailored meals to postpartum women. This is a pilot study of medically-tailored meals for new mothers whose pregnancies were complicated by gestational diabetes, and whose total gestational weight gain exceeded recommendations. Study will enroll 30 women with gestational diabetes and excessive gestational weight gain late in the third trimester of a singleton pregnancy. Data collection and intervention activities will begin after delivery. All participants will wear a continuous glucose monitor for baseline (first 2 weeks after delivery) and at follow up (after 3 months). Participants will also completed self-administered questionnaires, receive weekly informational videos by email, and have 3 monthly in-person check-ins with a member of the study team. Twenty participants will be randomly assigned to a medically-tailored meals intervention and 10 to a usual-care comparison group. A local community-based program will prepare and deliver 10 medically-tailored meals per week to intervention participants for their first 3 months postpartum.
BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare disease seen in the general population and has been reported as showing an increased incidence in the peritoneal dialysis (PD) population, as documented in case reports.
METHODS: We conducted a case-control study using data from the Taichung Veterans General Hospital electric medical record database from the years 2010 to 2023. We defined cases as CIDP with End-stage kidney disease (ESKD) and controls as without CIDP. A logistic regression analysis was used to investigate the association between CIDP and dialysis modality, age, gender, dialysis duration, plasma potassium > 5.5 mEq/L and < 2.5 mEq/L, and intact parathyroid hormone (i-PTH) > 613 pg/mL.
RESULTS: Our findings suggest that PD may be a risk factor in the ESKD population (Odds ratio: 5.125, C.I.: 1.078 ~ 24.372, p = 0.040) according to logistic regression analysis. Dialysis duration, gender, diabetes mellitus, HbA1c > 7%, hypokalemia, hyperkalemia, and hyperparathyroidism did not show an association with CIDP.
CONCLUSION: There seems to be an association between PD and CIDP in this case-control study. Possible mechanisms may involve systemic inflammation induced by peritoneal dialysate exchange or the content of the dialysate. Further studies are still needed.
The invention relates to a method for the event-controlled setting of boundaries in a monitoring process for a dialysis machine (110) to check whether boundaries are being respected. In the method, a plurality of boundary-related events that must be respected during the device monitoring process are established (1000), each of which can be stored as a state variable in a state vector. Reference state vectors (R-ZV) linked in each case to a target boundary setting (Z-GW) are also established (2000). Then, in a monitoring phase, measurement signals (e.g. volume of blood currently being pumped, pressure in the venous branch etc.) for the state variables are obtained (3000) in order to calculate a measurement signal vector. The calculated measurement signal vector is then compared (4000) with the established reference state vector (R-ZV), and if they match the dialysis machine (110) is controlled (6000) by a monitoring process (7000) using the target boundaries (Z-GW). The dialysis machine (110) is then controlled and monitored to check whether the previously set target boundaries (Z-GW) are being respected. The invention also relates to a boundary setting device (200).
Epilepsy is a condition marked by sudden, self-sustained, and recurring brain events, showcasing unique electro-clinical and neuropathological phenomena that can alter the structure and functioning of the brain, resulting in diverse manifestations. Antiepileptic drugs (AEDs) can be very effective in 30% of patients in controlling seizures. Several factors contribute to this: drug resistance, individual variability, side effects, complexity of epilepsy, incomplete understanding, comorbidities, drug interactions, and no adherence to treatment. Therefore, research into new AEDs is important for several reasons such as improved efficacy, reduced side effects, expanded treatment options, treatment for drug-resistant epilepsy, improved safety profiles, targeted therapies, and innovation and progress. Animal models serve as crucial biological tools for comprehending neuronal damage and aiding in the discovery of more effective new AEDs. The utilization of antioxidant agents that act on the central nervous system may serve as a supplementary approach in the secondary prevention of epilepsy, both in laboratory animals and potentially in humans. Chlorogenic acid (CGA) is a significant compound, widely prevalent in numerous medicinal and food plants, exhibiting an extensive spectrum of biological activities such as neuroprotection, antioxidant, anti-inflammatory, and analgesic effects, among others. In this research, we assessed the neuroprotective effects of commercially available CGA in Wistar rats submitted to lithium-pilocarpine-induced status epilepticus (SE) model. After 72-h induction of SE, rats received thiopental and were treated for three consecutive days (1st, 2nd, and 3rd doses). Next, brains were collected and studied histologically for viable cells in the hippocampus with staining for cresyl-violet (Nissl staining) and for degenerating cells with Fluoro-Jade C (FJC) staining. Moreover, to evaluate oxidative stress, the presence of malondialdehyde (MDA) and superoxide dismutase (SOD) was quantified. Rats administered with CGA (30 mg/kg) demonstrated a significant decrease of 59% in the number of hippocampal cell loss in the CA3, and of 48% in the hilus layers after SE. A significant reduction of 75% in the cell loss in the CA3, shown by FJC+ staining, was also observed with the administration of CGA (30 mg/kg). Furthermore, significant decreases of 49% in MDA production and 72% in the activity of SOD were seen, when compared to animals subjected to SE that received vehicle. This study introduces a novel finding: the administration of CGA at a dosage of 30 mg/kg effectively reduced oxidative stress induced by lithium-pilocarpine, with its effects lasting until the peak of neural damage 72 h following the onset of SE. Overall, the research and development of new AEDs are essential for advancing epilepsy treatment, improving patient outcomes, and ultimately enhancing the quality of life for individuals living with epilepsy.
One of the main hypothesis for the etiology of Inflammatory bowel disease (IBD) is an inappropriate and ongoing activation of the mucosal immune system in response to the presence of normal luminal flora. This aberrant response is most likely facilitated by defects in both the barrier function and the mucosal immune system of the intestinal epithelium. Syndecans are a class proteoglycans that take part in both cell adhesion and growth factor binding. Of the four known syndecan core proteins, syndecan-1 (CD138) and one of the best studied of this group and is also the relevant to the this study as it is expressed on the basolateral surface of columnar epithelial cells of the colon. Syndecan-1 functions as an integral membrane protein that participates in cell proliferation, cell migration and cell matrix interactions in the GI tract. Evidence for a reduction of syndecan-1 expression in the regenerating epithelium that overlies inflamed tissue was reported in both acute and chronic inflammation. This protein that is lost from the inflamed mucosal membrane might shed to the serum. Elevated serum levels of syndecan-1 may be predictive of disease presence and extent.
Approximately 165 participants will be randomly assigned to this arm and will receive the YMHP intervention over the course of the first 3 months. Months 3-12 will be inactive, and they will be followed for a total of 12 months.
Safety and effectiveness in patients 10 to 17 years of age with heFH have been evaluated in controlled clinical trials of 48 weeks duration in adolescent boys and controlled clinical trials of 24 weeks duration in girls who were at least 1 year post-menarche. Patients treated with lovastatin had an adverse experience profile generally similar to that of patients treated with placebo. Doses greater than 40 mg have not been studied in this population. In these limited controlled studies, there was no detectable effect on growth or sexual maturation in the adolescent boys or on menstrual cycle length in girls. See CLINICAL PHARMACOLOGY, Clinical Studies in Adolescent Patients; ADVERSE REACTIONS, Adolescent Patients; and DOSAGE AND ADMINISTRATION, Adolescent Patients (10 to 17 years of age) with Heterozygous Familial Hypercholesterolemia. Adolescent females should be counseled on appropriate contraceptive methods while on lovastatin therapy (see CONTRAINDICATIONS and PRECAUTIONS, Pregnancy). Lovastatin has not been studied in pre-pubertal patients or patients younger than 10 years of age.
OBJECTIVE: Eriocheir sinensis is a significant crustacean in freshwater aquaculture. However, this industry is vulnerable to diseases, including intestinal inflammation. Cadmium (Cd) is a water pollutant that exacerbates intestinal inflammation in Eriocheir sinensis. This study aimed to investigate the mechanisms of Cd-induced intestinal inflammation in Eriocheir sinensis and to identify potential therapeutic agents.
METHODS: Histology, enzyme activity, and gene expression detection were combined to investigate the promoting effect of Cd on the exacerbation of intestinal inflammation in Eriocheir sinensis. Transcriptome sequencing was performed to analyze the critical signaling pathways regulating intestinal inflammation in Eriocheir sinensis.
RESULTS: Transcriptome analysis confirmed that the Toll-like receptor pathway is critical in this process. TLR4-IN-C34, a specific inhibitor of TLR4, was identified as a potential treatment for intestinal inflammation. In vivo results demonstrated that TLR4-IN-C34 effectively reduced the severity of Cd-induced intestinal inflammation in Eriocheir sinensis. The tissue morphology of the intestine, gills, and hepatopancreas of Eriocheir sinensis improved, showing a significant decrease in inflammatory factors and apoptotic genes, along with enhanced antioxidant activity.
CONCLUSIONS: In conclusion, this study indicates that the water pollutant Cd exacerbates intestinal inflammation in Eriocheir sinensis, and TLR4-IN-C34 regulates the Toll-like receptor pathway in treating intestinal inflammation. This research provides valuable insights into the management of intestinal inflammation and the sustainable cultivation of Eriocheir sinensis.
Participants with recurrent craniopharyngioma will receive one (1) dose of nivolumab within 14 days - 5 days prior to planned biopsy or resection. At completion of biopsy or resection, participants having undergone biopsy only or STR or NTR will continue on combination maintenance therapy of nivolumab given every 2 weeks and Tovorafenib once weekly at the respected RP2D for each agent. If participants are eligible based on archival tissue alone, these participants will go directly on to receive combination therapy only.
Participants will be monitored via a transdermal monitor for four weeks. They will give four breath samples a day for these weeks as well as 5 Blood spot samples.
This is a single-center, single-operator, investigator-initiated, investigator-funded, open-label, non-randomized cohort study. Inclusion criteria include patients ≥18 years, secundum atrial septal defect (ASD) ≤1cm on transesophageal echocardiography or patent foramen ovale (PFO), without contraindications to antiplatelet and/or antithrombotic therapy, and suitable anatomy for device closure with one of the following: Amplatzer atrial septal occluder, Amplatzer Cribriform septal occluder, Amplatzer PFO occluder, or the Gore Helex septal occluder. After device implantation, routine clinical followup will be performed, including transthoracic echocardiography at 1 day, 1 month, and 6 months, and 48-Holter monitoring for arrhythmia at 1 month.

Research related study procedures are blood draws to measure nickel levels and a patient questionnaire about symptoms. Blood draws will be done at baseline \[from the femoral venous sheath immediately prior to device implantation\] and at one (1) day, one (1) month, three (3) months and six (6) months. The Questionnaire will be completed at one (1) month, three (3) months and six (6) months but can be done over the telephone if patient is having blood drawn at a lab closer to their home. Patient participation is complete after collection of the 6 month blood results and patient questionnaire.
An emergence of multidrug-resistant (MDR) Staphylococcus haemolyticus has been observed in the neonatal intensive care unit (NICU) of Nîmes University Hospital in southern France. A case-control analysis was conducted on 96 neonates, to identify risk factors associated with S. haemolyticus infection, focusing on clinical outcomes. Forty-eight MDR S. haemolyticus strains, isolated from neonates between October 2019 and July 2022, were investigated using routine in vitro procedures and whole-genome sequencing. Additionally, five S. haemolyticus isolates from adult patients were sequenced to identify clusters circulating within the hospital environment. The incidence of neonatal S. haemolyticus was significantly associated with low birth weight, lower gestational age, and central catheter use (p < 0.001). Sepsis was the most frequent clinical manifestation in this series (20/46, 43.5%) and was associated with five deaths. Based on whole-genome analysis, three S. haemolyticus genotypes were predicted: ST1 (6/53, 11%), ST25 (3/53, 5.7%), and ST29 (44/53, 83%), which included the subcluster II-A, predominantly emerging in the neonatal department. All strains were profiled in silico to be resistant to methicillin, erythromycin, aminoglycosides, and fluoroquinolones, consistent with in vitro antibiotic susceptibility tests. Moreover, in silico prediction of biofilm formation and virulence-encoding genes supported the association of ST29 with severe clinical outcomes, while the persistence in the NICU could be explained by the presence of antiseptic and heavy metal resistance-encoding genes. The clonality of S. haemolyticus ST29 subcluster II-A isolates confirms healthcare transmission causing severe infections. Based on these results, reinforced hygiene measures are necessary to eradicate the nosocomial transmission of MDR strains.
<P>PROBLEM TO BE SOLVED: To provide an ozonized vegetable oil which is one of excellent methods for storing ozone in a form usable for applications of deodorization, bacterial removal and decoloration.  <P>SOLUTION: An ozone soap using the ozonized vegetable oil as a main raw material is provided. The ozonized vegetable oil can be used in the same manner as that of usual soap in applications where the soap can be used such as hand-washing with the soap or washing of clothes or during bathing of pets by providing the ozonized vegetable oil as the soap. As a result, e.g. fish smell clinging to hands during fish cooking can be removed simultaneously with the bacterial removal when the hand-washing is carried out with the ozone soap.  <P>COPYRIGHT: (C)2007,JPO&INPIT
1,211,171. Thieno-benzothiazepines. J. R. GEIGY A.G. 29 Nov., 1968 [30 Nov., 1967; 29 Dec., 1967], No. 56702/68. Heading C2C. Novel thieno-benzothiazepines of Formula (I) in which n is 2 or 3, R is hydrogen or methyl, X is hydrogen or chlorine and Z is hydrogen, C 1-4 alkyl, C 1-4 hydroxyalkyl, C 3-9 alkanoyloxyalkyl or cyclopropyl, and their acid addition salts, are prepared by reacting a compound of Formula (II) in which Q is halogen or C 1-4 alkoxy, with a compound of Formula (III) in which Z has the same meaning as Z or it represents a radical which can be replaced by hydrogen by hydrolysis, or an alkali metal derivative thereof, if necessary hydrolysing the product obtained to convert the radical Z<SP>1</SP>. into hydrogen, optionally converting a product obtained, in which Z is hydrogen, into a product in which Z is a C 1-4 alkyl, C 1-4 hydroxyalkyl or C 3-9 alkanoyloxyalkyl group, or acylating a product in which Z is C 1-4 hydroxyalkyl, into one in which Z is C 3-9 alkanoyloxyalkyl, or hydrolysing a product obtained in which Z is C 3-9 alkanoyloxyalkyl into one in which Z is C 1-4 hydroxyalkyl, and if desired, converting a compound of Formula (I) obtained into an acid addition salt. Starting materials of Formula (II), in which Q is chlorine, are prepared by reacting a compound of Formula (IV) with phosphorus pentachloride. The compound of Formula (II), in which X is hydrogen and Q is ethoxy, is prepared by reacting the corresponding compound, in which Q is chlorine, with ethanol. Thieno - benzothiorepinones of Formula (IV) are prepared by reacting 2-amino-thiophenol or 2-amino-4-chloro-thiophenol with 3-bromothiophene to give a (3-thienylthio)-aniline, reacting this with phosgene to give a (3-thienylthio)-phenyl isocyanate and cyclizing this using aluminium chloride. Pharmaceutical compositions having a central depressant action, for oral, rectal or parenteral administration, comprise a compound of Formula (I), or a pharmaceutically acceptable acid addition salt thereof, together with a carrier.
[GB1211171A]
PURPOSE: A nanocomposite and a pharmaceutical composition containing the same are provided to ensure therapeutic action through cell signaling and electromagnetic radiation without side effects. CONSTITUTION: A nanocomposite contains: a core containing biodegradable nanoparticles; and a metal ingredient which generates heat by electromagnetic radiation of 700-1,000 nm. The nanoparticles are calcium phosphate, apatite, or biodegradable polymers. The metal ingredient is gold, platinum, silver, copper, titanium, or chrome. A method for preparing the nanocomposite comprises: a step of introducing the metal particles to the surface of the biodegradable nanoparticles; and a step of forming a coating layer on the surface of nanoparticles. A pharmaceutical composition for treating cell disorder contains the nanocomposite and pharmaceutically acceptable carrier.
Of these participants taking the Maximum tolerated dose, up to 15 will undergo a biopsy. Progression free survival will be the primary objective of this study phase.
Unilateral Cerebral Palsy (UCP) represents the most frequent form of CP; the upper limb (UL) is generally more affected than the lower limb with an impact in "activity" and "participation" areas. The non-invasive brain stimulation techniques (NIBS), such as transcranial Direct Current Stimulation (tDCS), appear able to modulate neuronal plasticity processes even more late in age attracting great interest for their potential fallout in the field of rehabilitation. The effects of tDCS in recovery of motor function has more investigated in adults, while in the pediatric population studies on safety and efficacy are still few and not conclusive. This study aims to evaluate the safety and the feasibility of tDCS session in children and young adults with UCP both in short term and in follow up (up to 24 hrs after the tDCS session). Secondarily it aims to test the effects of tDCS (real vs sham) in improving, in short term, UL functions. For the study 6 children (aged 10-17 years) and 6 young adults (aged 18-28 years) with UCP will be recruited. Each subject receives, randomly, a real session and a sham session of tDCS with BrainStim Stimulator. Before (T0), immediately after (T1) and after 1 hour and half (T2) to each tDCS session (real or sham) heart rate, blood pressure and UL functions will be measured. Moreover the subject fills in an ad hoc questionnaire on safety at T1 and T2 and, on call, at 24 hours after the sessions (T3).
Ambispective patients should have initiated Ribociclib, in combination with hormonal therapy, for at least 12 months before the patient's recruitment date and are still on Ribociclib in combination with hormonal therapy at recruitment. These patients will be followed up till progression, death, Ribociclib discontinuation due to adverse events, or till a maximum period of 6 months, whichever comes first.